FDA Approved Products

1,302 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Active:Lifecycle: PeakClear all
VIVLODEX
meloxicam
Peak
ORAL · CAPSULE
2015
NDA
0/100
VIZIMPRO
dacomitinib
Peak
Pfizer
ORAL · TABLET
2018
SMNDA
0/100
VOGELXO
testosterone
Peak
TRANSDERMAL · GEL, METERED
2014
NDA
0/100
VOSEVI
sofosbuvir, velpatasvir, and voxilaprevir
Peak
Gilead Sciences
ORAL · TABLET
2017
SMNDA
0/100
VOXZOGO
vosoritide
Peak
BioMarin Pharmaceutical
SUBCUTANEOUS · POWDER
2021
PeptideNDA
0/100
VTAMA
tapinarof
Peak
Merck & Co.
TOPICAL · CREAM
2022
NDA
0/100
VUITY
pilocarpine hydrochloride
Peak
AbbVie
OPHTHALMIC · SOLUTION/DROPS
2021
NDA
0/100
VUMERITY
diroximel fumarate
Peak
Biogen
ORAL · CAPSULE, DELAYED RELEASE
2019
NDA
0/100
VYLEESI (AUTOINJECTOR)
bremelanotide
Peak
SUBCUTANEOUS · SOLUTION
2019
PeptideNDA
0/100
VYNDAMAX
tafamidis
Peak
Pfizer
ORAL · CAPSULE
2019
NDA
0/100
VYXEOS
(daunorubicin and cytarabine) liposome
Peak
Jazz Pharmaceuticals
INTRAVENOUS · POWDER
2017
NDA
0/100
WEGOVY
semaglutide
Peak
Novo Nordisk
SUBCUTANEOUS · SOLUTION
2021
PeptideNDA
0/100
WELIREG
belzutifan
Peak
Merck & Co.
ORAL · TABLET
2021
NDA
0/100
WYNZORA
calcipotriene and betamethasone dipropionate
Peak
TOPICAL · CREAM
2020
NDA
0/100
XACIATO
clindamycin phosphate
Peak
Merck & Co.
VAGINAL · GEL
bacterial vaginosis in females 12 yearsClinical Studies ()]
2021
NDA
0/100
XADAGO
safinamide mesylate
Peak
ORAL · TABLET
2017
NDA
0/100
XARACOLL
bupivacaine hydrochloride
Peak
IMPLANTATION · IMPLANT
2020
NDA
0/100
XARELTO
rivaroxaban
Peak
Johnson & Johnson
ORAL · TABLET
2011
NDA
0/100
XARTEMIS XR
acetaminophen; oxycodone hydrochloride
Peak
ORAL · TABLET, EXTENDED RELEASE
2014
NDA
0/100
XATMEP
methotrexate
Peak
R-Pharm US
ORAL · SOLUTION
2017
NDA
0/100
XCOPRI
cenobamate
Peak
SK Life Science
ORAL · TABLET
2019
NDA
0/100
XEGLYZE
abametapir
Peak
TOPICAL · LOTION
2020
NDA
0/100
XELJANZ XR
tofacitinib citrate
Peak
Pfizer
ORAL · TABLET, EXTENDED RELEASE
2016
NDA
0/100
XELSTRYM
dextroamphetamine
Peak
Noven Pharmaceuticals
TRANSDERMAL · SYSTEM
2022
NDA
0/100